A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
The company is starting four new pivotal trials this year.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The company quietly deprioritises AlphaMedix.
RMC-5127 becomes the company’s fourth clinical project.
Tecvayli and Hernexeos might get speedy approval decisions.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
